文献速递神经核医学

阿尔茨海默病神经病理分期与淀粉样蛋白及tau闪烁显像生物标志物的相关性

Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers.
PubMed 文献 · J Nucl Med · 2020-08-06

本文综述了美国国家老龄化研究所-阿尔茨海默协会(NIA-AA)神经病理评分系统的三个要素(Thal Aβ相、Braak神经原纤维缠结分期、CERAD神经炎性斑块评分),并讨论了现有证据表明这些要素与Aβ PET和tau PET显像表现的相关性。文章指出PET生物标志物已改变AD治疗试验设计,将重点转向临床前阶段。

要点

  • NIA-AA神经病理评分由Thal Aβ相、Braak分期和CERAD评分三个要素复合构成。
  • Aβ PET和tau PET可作为AD连续体的体内生物标志物,反映神经病理改变。
  • AD神经病理改变可在临床症状出现前长达25年开始。

核心结论

  • NIA-AA神经病理评分系统基于Thal Aβ相、Braak神经原纤维缠结分期和CERAD神经炎性斑块评分三个要素。
  • 现有证据表明Aβ和tau PET显像表现与上述神经病理要素相关,有助于解读医师理解显像意义。

研究设计与样本

  • 本文为综述,回顾NIA-AA评分系统的三个要素并讨论其与Aβ和tau PET显像表现关系的现有证据。

主要发现

  • AD连续体的神经病理改变可在临床症状出现前长达25年开始。
  • Aβ靶向显像剂已获FDA批准,tau靶向显像剂中有一种于2020年5月获批。
  • PET生物标志物已改变AD治疗试验设计,将重点转向临床前阶段。

关键数值与推荐

  • NIA-AA指南定义死后AD神经病理改变为基于三个要素的复合评分:Thal Aβ相、Braak分期和CERAD评分。
  • Thal Aβ相描述大脑Aβ受累(扩散)范围,Braak分期描述神经原纤维缠结(过度磷酸化tau蛋白构成)受累范围,CERAD评分描述新皮质关键部位神经炎性斑块密度。

临床怎么用

  • 解读医师应理解AD进行性神经病理改变及其与闪烁显像表现的关系,以充分认识显像发现的意义并作为解读检查的基础。
  • 未来疾病修饰治疗将依赖已批准或研究中生物标志物确认靶病理的存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PET neuroimaging of amyloid-β (Aβ) provides an in vivo biomarker for pathologic changes associated with Alzheimer disease (AD). Aβ-targeted agents have been approved by the Food and Drug Administration, with additional agents, most notably targeting tau, currently under clinical investigation and one approved in May 2020. These agents, along with nonscintigraphic biomarkers from blood and cerebrospinal fluid, have provided an opportunity to investigate the pathogenesis, prodromal changes, and time course of the disease in living individuals. The current understanding is that the neuropathologic changes of the AD continuum begin up to 25 y before the onset of clinical symptomatology. The opportunities afforded by in vivo biomarkers of AD, whether by serum, cerebrospinal fluid examination or PET, have transformed the design of AD therapeutic trials by shifting focus to the preclinical stages of disease. Future disease-modifying therapies, should they be forthcoming, will rely heavily on the use of approved biomarkers or biomarkers currently under investigation to confirm the presence of target pathology. Understanding the progressive neuropathologic changes that occur in AD-and how scintigraphic findings relate to these changes-will help the interpreting physician to fully appreciate the implications of the scintigraphic findings and provide a basis to interpret the examinations. The recently adopted National Institute on Aging-Alzheimer Association guidelines define postmortem AD neuropathologic changes as a composite score based on 3 elements. These elements are the extent of involvement (spread) by cerebral Aβ based on the progression model defined by the Thal Aβ phases, the extent of involvement (spread) by neurofibrillary tangles (composed of hyperphosphorylated tau proteins) based on the progression model defined by Braak, and the Consortium to Establish a Registry for Alzheimer's Disease score, which describes the density of neuritic plaques based on certain key locations in the neocortex. This paper will review the 3 elements that define the National Institute on Aging-Alzheimer's Association scoring system and discusses current evidence on how these elements relate to findings based on Aβ and tau PET scintigraphy.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Koychev I, Hofer M, Friedman N, et al. Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers. J Nucl Med. 2020. PMID: 32764121. doi:10.2967/jnumed.119.230458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。